Viva BioInnovator

Proviva Therapeutics is a pro-drug design platform for cytokines and other fusion proteins. It is committed to solving the problem of drug metabolism and the delivery of cytogenic drugs.

TechnoDerma Medicines is a private clinical-stage biopharmaceutical company dedicated to the development of innovative therapies for various skin diseases. The company focuses on creating small molecular drugs aimed at treating conditions such as androgenetic alopecia, atopic dermatitis, psoriasis, lupus erythematosus, and scars. By prioritizing research and development, TechnoDerma Medicines seeks to provide patients with safe and effective treatment options to improve their quality of life and address unmet medical needs in dermatological care.

Anji Pharmaceuticals is focused on tackling high-value targets validated by human genetics. We are exhaustive in our discovery and clinical efforts while nimble in our strategy and execution. We have assembled a world-class team of scientist entrepreneurs who are committed to accelerate innovative medicines in China and worldwide.

Full Circles Therapeutics is a biotechnology company dedicated to developing innovative genome surgery platforms aimed at treating genetic diseases and cancer. The company specializes in creating a viral-free genome surgery platform that allows for the precise insertion of genetic sequences of varying sizes at specific locations within the human genome of disease-relevant cells. This technology is designed to facilitate the effective treatment of severe genetic disorders and various forms of cancer, offering new possibilities for curative genomic medicine. Through its focus on discovery, development, manufacturing, and commercialization, Full Circles Therapeutics aims to advance the field of genetic medicine and improve patient outcomes.

Exarta Therapeutics is a preclinical biopharmaceutical company focused on developing novel therapies for cancer treatment. Operating discreetly, the company aims to create innovative drug candidates targeting cancer tumours without yet having any products in clinical trials or publicly available data.

Calira Therapeutics is a biotech company focusing on allosteric inhibitors of CaMK2 for the treatment of diabetes and heart failure.

DEKA Biosciences is an early-stage biotechnology company focused on developing next-generation cytokine therapeutics aimed at treating cancer and inflammatory diseases. The company creates therapies with disease-specific applications that enhance patient outcomes by optimizing pharmacokinetics and pharmacodynamics through the targeted delivery of dual and complementary cytokines to affected tissues or cells. This innovative approach seeks to provide patients with curative treatment options for various conditions, including cancer, autoimmune disorders, and infectious diseases.

i2O Therapeutics, established in 2019 and headquartered in Saratoga, California, specializes in converting injectable biologic therapies into orally administrable pills using its proprietary ionic liquid technology. This innovative approach aims to enhance the permeability of epithelial barriers, enabling safe and effective oral delivery of peptides, proteins, and other traditionally injected drugs. The company focuses on developing next-generation oral therapies for metabolic and inflammatory diseases.

Reglagene LLC, founded in 2016 and based in Tucson, Arizona, specializes in transforming tubulin therapy for brain diseases. The company leverages its expertise in designing and developing brain-penetrant medicines to create innovative therapies for the safe and effective treatment of central nervous system diseases. Reglagene's lead program focuses on a novel, orally administered therapy that can penetrate the blood-brain barrier, targeting brain cancers. Additionally, the company's portfolio includes indications driven by brain inflammation and ocular neovascularization, aiming to address conditions where changes in gene processing rates are causal.

WM Therapeutics is a drug discovery company that discovers and develops novel cancer therapies that limit tumor-autonomous growth and stimulate the immune system to attack the tumor.

F5 Therapeutics focuses on precision-based protein degradation to eliminate disease-causing proteins that are resistant to conventional treatment methods. The company specializes in developing targeted protein degraders, including small molecule drugs and molecular glues, aimed at various conditions such as oncology, immuno-oncology, autoimmune diseases, and fibrosis. By employing proprietary techniques for discovering novel targets for protein degradation, F5 Therapeutics enables researchers to create targeted therapies with unique degradation profiles. This approach not only facilitates the understanding of critical signaling pathways in stem cells during embryonic development but also supports homeostasis and regeneration in adult organisms.

NAKI Therapeutics is a biopharmaceutical company specializing in research and development of Chimeric Antigen Receptor (CAR)-Natural Killer (NK) immunotherapy. Its innovative approach aims to effectively and safely eliminate cancer cells compared to existing treatments.

Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, focused on the discovery and early development of therapeutic drugs targeting G protein-coupled receptors (GPCRs), which are key drug targets in various diseases. Founded in 2001, the company specializes in developing small molecules for the treatment of central nervous system (CNS) disorders and cancer. It employs its proprietary technology platform, DTect-All, which enables the identification of orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs) that are challenging to discover using conventional methods. In addition, Domain Therapeutics offers BioSens-All, a platform to explore the signaling complexities associated with GPCR activation, enhancing its ability to address difficult targets, such as orphan and peptidic GPCRs.

GT Apeiron Therapeutics is a developer of innovative drugs utilizing artificial intelligence technology. The company develops breakthrough investigational medicines by harnessing the power of artificial intelligence, aiming to drastically increase efficiency throughout the drug discovery process.

ArrePath is a biotechnology company focused on developing innovative therapies to combat drug-resistant infections. Its proprietary platform enables the creation of new medicines targeting multiple pathways, potentially enhancing efficacy and reducing development risks.

HAYA Therapeutics develops RNA-based therapeutics focused on treating fibrotic diseases. Its precision medicines target specific regulators of fibrosis in tissues like the heart, aiming to block fibrosis progression and treat associated conditions safely and effectively.

XLement provides all-around intelligent medical testing products and programs for medical institutions and consumers.

Bichen Pharmaceutical is a small-molecule tumor-targeted drug developer for the treatment of various malignant tumors and brain metastases.

Amberstone Biosciences is a biotechnology company focused on discovering novel immunotherapies aimed at addressing challenging medical targets that traditional methods struggle to tackle. The company utilizes its proprietary microfluidics-powered AmberFlow drug-discovery platform, which allows for the analysis of single-cell function within a customizable microenvironment. This innovative approach, combined with the expertise of its team in immuno-oncology and single-cell assay biology, positions Amberstone to develop transformative therapeutic antibodies that cater to patients with unmet medical needs. Through creative partnerships and advanced technologies, Amberstone Biosciences seeks to overcome conventional limitations in therapeutic development, ultimately enhancing patient care and outcomes.

Focus-X Therapeutics is a preclinical-stage biotechnology company specializing in the development of radiopharmaceuticals for cancer diagnosis and treatment. The company addresses unmet medical needs in oncology, particularly for solid tumors with low five-year survival rates. Focus-X Therapeutics employs a theragnostic approach, utilizing proprietary radioligand therapy (RLT) to deliver precise alpha or beta emitters that target and disrupt cancer cell DNA. By optimizing peptide ligand vectors, the company aims to innovate radioligand theranostic agents, offering healthcare professionals new therapeutic options in the fight against cancer.

Flash Therapeutics develops drug candidates to selectively target leukemic stem cells and prevent AML relapse.

Tatara Therapeutics is a pre-clinical stage biotechnology company dedicated to developing precision medicine solutions for cancer treatment. The company leverages its proprietary iron-activated drug conjugate technology to create therapeutics that exploit metabolic changes in iron homeostasis caused by mutant RAS and other oncogenes. By focusing on the mechanisms of ferroptosis and ferrous addictions, Tatara Therapeutics aims to enhance the detection and targeting of cancer-causing tumors, thereby improving treatment outcomes for patients. Its innovative approach positions the company at the forefront of cancer therapeutics, emphasizing the importance of metabolic factors in the development and progression of cancer.

Ornovi is a pre-clinical stage therapeutics company developing treatments for inflammatory and autoimmune diseases. The company focuses on a selective JAK3/ITK dual inhibitor for the treatment of alopecia areata, vitiligo, and other inflammatory and autoimmune diseases.

QureBio focuses on the research and development of innovative macromolecular biopharmaceuticals. Its goal is to develop new therapeutic drugs for the treatment of refractory cancer, autoimmune diseases, and metabolic diseases in China and the world to benefit patients. QureBio has multiple technology platforms for antibody drug development including phage display technology platforms and hybridoma antibodies technology platform and monoclonal antibody platform. The company was founded in 2017 and is based in Pudong District, Shanghai.

Fuse Biotherapeutics is a biotechnology company focused on developing innovative immune-modulating therapeutics aimed at treating cancer. Founded in 2021 and based in Los Angeles, CA, the company employs a strategic approach to immune response, ensuring that strong reactions to cancerous threats are achieved while preserving the body's natural mechanisms that protect healthy tissues. This method positions Fuse Biotherapeutics to create effective new treatment options that may outperform existing therapies in the oncology landscape.

DEKA Biosciences is an early-stage biotechnology company focused on developing next-generation cytokine therapeutics aimed at treating cancer and inflammatory diseases. The company creates therapies with disease-specific applications that enhance patient outcomes by optimizing pharmacokinetics and pharmacodynamics through the targeted delivery of dual and complementary cytokines to affected tissues or cells. This innovative approach seeks to provide patients with curative treatment options for various conditions, including cancer, autoimmune disorders, and infectious diseases.

Nerio Therapeutics is a biotechnology company focused on the life sciences sector. It was founded in 2019 and is based in La Jolla, CA, USA.

IpiNovyx Bio is a biopharmaceutical company focused on creating a novel platform of immunoproteasome-modulating therapeutics aimed at improving the treatment of autoimmune and inflammatory diseases. The company's innovative approach involves developing inhibitors that selectively target the immunoproteasome, which plays a critical role in regulating specific immune cell types. By modulating these immune responses, IpiNovyx Bio seeks to enable patients to recover more effectively from their conditions and enhance their overall health.

Founded in 2019, Karma Biotechnologies is a Los Angeles-based company dedicated to developing therapies for autoimmune diseases, allergies, and food sensitivities. It specializes in antigen-specific immunotherapies using lipid nanoparticle engineering.

Founded in 2013 and headquartered in Raleigh, North Carolina, Evecxia Therapeutics is a pharmaceutical company dedicated to developing drugs for patients with disabling neuropsychiatric conditions. Its primary focus is on EVX-101, aimed at treating depression and other costly neuropsychiatric disorders where current therapies are insufficient.

Aleta Biotherapeutics, Inc., founded in 2015 and based in Natick, Massachusetts, is an immuno-oncology company dedicated to developing innovative cellular therapeutics aimed at addressing a wide range of cancer indications. The company's focus is on transforming cellular therapies to target various tumor types, including challenging and often intractable solid tumors. By advancing these therapeutic approaches, Aleta Biotherapeutics seeks to enhance treatment options for healthcare professionals, ultimately improving patient outcomes in the fight against cancer.

Grove Biopharma is a biotechnology company specializing in materials science solutions for peptide therapeutics. It focuses on discovering and developing novel 'protein-like polymers' to address significant unmet medical needs in chronic inflammatory and neurodegenerative diseases.

Telo Therapeutics is a biotechnology company focused on developing innovative cancer therapeutics aimed at reversing cancer cell immortality. The company employs a precision medicine approach to target telomerase, an enzyme that cancer cells utilize during the immortalization process. By inhibiting this enzyme, Telo Therapeutics seeks to leave healthy cells unscathed while improving treatment outcomes for patients who have exhausted other options. Through its unique platform, the company aspires to enhance survival and well-being in cancer patients, ultimately contributing to more effective treatment strategies and potential cures for various forms of cancer.

HAYA Therapeutics develops RNA-based therapeutics focused on treating fibrotic diseases. Its precision medicines target specific regulators of fibrosis in tissues like the heart, aiming to block fibrosis progression and treat associated conditions safely and effectively.

HAYA Therapeutics develops RNA-based therapeutics focused on treating fibrotic diseases. Its precision medicines target specific regulators of fibrosis in tissues like the heart, aiming to block fibrosis progression and treat associated conditions safely and effectively.

Cybrexa Therapeutics is a biotechnology company focused on developing an innovative class of small molecule DNA repair inhibitors aimed at improving cancer treatment. Founded in 2016 and based in New Haven, Connecticut, Cybrexa utilizes a proprietary peptide-based technology that specifically targets the tumor microenvironment. This approach allows for enhanced drug delivery and increased therapeutic efficacy, particularly when combined with existing chemotherapies and radiotherapies. By enabling the safe administration of higher drug doses, Cybrexa's therapeutics aim to expand the efficacy of current anticancer agents and address significant unmet medical needs in oncology. The company's novel platform has the potential to redefine drug delivery paradigms and enhance patient outcomes in cancer care.

DTx Pharma, LLC is a biotechnology company headquartered in San Diego, California, specializing in the development and commercialization of fatty acid-conjugated peptide therapeutics. Founded in 2017, the company focuses on delivering RNA-based medicines to treat patients with rare and chronic diseases, including retinitis pigmentosa, Duchenne muscular dystrophy, and various central nervous system disorders. DTx Pharma's innovative delivery technology addresses challenges faced by previous-generation platforms, such as poor pharmacokinetics and limited cellular uptake, thereby enhancing the efficiency of nucleic acid drug delivery across diverse tissues and cell types. The company aims to establish RNA therapeutics as a leading option for personalized treatment in multiple therapeutic areas.

AmacaThera Inc. is a clinical-stage biotechnology company based in Toronto, Canada, founded in 2016. The company is focused on developing an innovative injectable hydrogel platform technology designed to enhance drug delivery and improve patient outcomes in various medical applications, particularly in post-surgical pain management, cancer treatment, and other challenging therapeutic areas. AmacaThera's technology features a unique fast-gelling material that liquefies under mechanical force, consisting of a reversible blend of hyaluronan and methylcellulose. This approach allows for localized and sustained drug delivery, potentially reducing postoperative pain and addressing other medical needs effectively.

Iterion Therapeutics, Inc. is a clinical-stage biotechnology company based in Houston, Texas, focused on developing innovative therapeutics for cancer treatment. Established in 2010, the company specializes in targeted cancer therapies, with its lead product, Tegavivint, serving as a potent and selective inhibitor of the Wnt/b-catenin signaling pathway. This pathway is known to play a critical role in various cancer-related processes, including cell proliferation and immune evasion. Tegavivint has demonstrated pre-clinical efficacy in several cancer models, such as desmoid tumors, acute myeloid leukemia, osteosarcoma, and various solid tumors. Iterion Therapeutics is actively enrolling patients in a Phase I clinical study of Tegavivint for desmoid tumors at multiple clinical centers across the United States and Canada.

Seraxis is a private biotechnology company established in March 2013, with operations in both Singapore and the United States. The company has a GMP lab located in Germantown, Maryland, where a team of scientists has developed innovative cell and encapsulation technologies. Seraxis is dedicated to creating a practical cell therapy aimed at treating insulin-dependent diabetes. Their primary objective is to provide a long-term cure for patients that does not necessitate the use of immunosuppression, thereby addressing a critical need in diabetes care. By focusing on the production of insulin to regulate glucose levels, Seraxis aims to enhance the quality of life for diabetic patients through its advanced therapeutic solutions.

Blue Oak Pharmaceuticals, Inc. is a pharmaceutical company focused on developing innovative drugs for brain disorders. Founded in 2016 and based in Concord, Massachusetts, the company employs a unique drug discovery paradigm that integrates custom-designed chemotypes with advanced technologies in behavioral profiling, synthetic chemistry, and brain imaging. Blue Oak's approach emphasizes in vivo phenotypic assays and systems-level neurobiology to identify first-in-class clinical candidates. The company aims to advance these candidates through early-phase proof-of-concept studies, utilizing translational medicine biomarkers to assess brain circuit activity. The team at Blue Oak comprises experts in neurobiology, medicinal chemistry, and informatics, fostering a collaborative environment that combines established partnerships with cutting-edge research methodologies.

Basking Biosciences is developing a reversible thrombolytic therapy to restore blood flow to the brain during ischemic stroke, with the aim of preventing hemorrhage and long-term damage. The platform combines a primary agent that targets clot stability with a designed reversal agent that can be administered if bleeding occurs to neutralize the active compound and restore normal clotting, enabling treatment for acute ischemic stroke.

Founded in 2017, Phenomic AI is a Toronto-based company that develops artificial intelligence-driven drug discovery platforms. Its technology analyzes phenotypes in complex disease models like high-content co-culture and 3D assays, enabling pharmaceutical companies to discover drugs more efficiently.

Sisu Pharma is focused on developing targeted therapies for patients with therapy-resistant prostate cancer, a condition that significantly impacts men's health worldwide. Prostate cancer ranks as the second most prevalent cancer among men, with over 1.3 million new cases reported globally in 2018. While various treatments exist, none provide a cure, often leading to resistance and ultimately, patient mortality. Sisu Pharma’s innovative approach centers on its proprietary technology that specifically targets Heat Shock Factor 1, a critical protein involved in the survival and progression of advanced prostate cancer. This targeted strategy not only aims to improve treatment outcomes for patients with limited options but also presents potential avenues for addressing neurodegenerative diseases and infections.

Elgia Therapeutics is a biotechnology company focused on developing innovative therapies for chronic inflammatory and fibrotic diseases. The company employs novel approaches to drug discovery, utilizing throughput chemical screening and structure-based design to identify and develop small molecule inhibitors targeting untapped protein pathways. By understanding the role of metabolic stress in driving inflammation and fibrosis, Elgia Therapeutics aims to create effective treatments for debilitating chronic conditions. Its commitment to addressing these complex health issues positions the company as a leader in the field of therapeutics and pharmaceuticals.

Antag Therapeutics ApS is a biotechnology company based in Copenhagen, Denmark, founded in 2017. The company specializes in developing peptide drugs aimed at treating dietary-related metabolic diseases, including obesity, diabetes, and non-alcoholic fatty liver disease. Antag Therapeutics focuses on creating peptide-based GIP receptor antagonists designed to manage these conditions by reducing blood flow and lipid uptake in adipose tissue. Through its innovative approach, the company seeks to address significant health challenges associated with metabolic disorders.

BioCasting Pharma is a clinical research company that provides humanized 3D disease model solutions based on microphysiological systems (MPS) for drug development institutions. It can currently provide system solutions for areas and products that are severely lacking preclinical evaluation tools, including infection/metabolism, tumor vascularization, gene and cell therapy, bispecific antibodies, and ADC.

Synthis Therapeutics is an early-stage biotechnology company focused on developing innovative immuno-oncology therapeutics aimed at improving patient outcomes in cancer treatment. The company’s unique therapeutic platform targets the immunosuppressive TGF-β pathway, which plays a significant role in cancer progression. By selectively addressing this pathway, Synthis aims to enhance immune function and safely improve the efficacy of cancer therapies, ultimately driving patient survival. Through this approach, healthcare professionals can utilize the power of the patients' immune systems to combat metastatic cancer effectively.

Saverna Therapeutics AG is a biotechnology company based in Allschwil, Switzerland, founded in 2017. The company specializes in drug discovery, utilizing a platform that integrates fragment-based screening, nuclear magnetic resonance spectroscopy, and machine learning to develop small molecule drugs. Its primary focus is on selectively targeting specific microRNAs (miRNAs) to address various disease areas, including inflammation, cancer, and infection. By leveraging advanced technologies, Saverna Therapeutics aims to create innovative therapeutic solutions that can effectively combat these diseases.

Bright Angel Therapeutics develops novel therapeutics targeting stress responses crucial for fungi's survival, virulence, and drug resistance. Its platform aims to enhance current treatment efficacy and eliminate drug resistance, combating life-threatening fungal infections.

AmacaThera Inc. is a clinical-stage biotechnology company based in Toronto, Canada, founded in 2016. The company is focused on developing an innovative injectable hydrogel platform technology designed to enhance drug delivery and improve patient outcomes in various medical applications, particularly in post-surgical pain management, cancer treatment, and other challenging therapeutic areas. AmacaThera's technology features a unique fast-gelling material that liquefies under mechanical force, consisting of a reversible blend of hyaluronan and methylcellulose. This approach allows for localized and sustained drug delivery, potentially reducing postoperative pain and addressing other medical needs effectively.

Argonaut Genomics is an early-stage biotech company that focuses on developing novel cancer antigens in solid tumors for therapeutic cancer vaccines and cell therapies.

Forkhead BioTherapeutics Inc. is a biopharmaceutical company focused on developing innovative oral therapies for insulin-dependent diabetes. Founded in 2017 and based in New York, the company is working on Foxin, an oral agent designed to target and delete the FOXO1 protein. This mechanism aims to restore normal insulin production and regulate glucose metabolism, potentially transforming the management of diabetes. Forkhead BioTherapeutics harnesses the natural processes of cell conversion and regeneration to create therapies that significantly enhance patients' lives.

QurAlis Corporation is a clinical-stage biotechnology company focused on discovering and developing therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Established in 2016 and based in Cambridge, Massachusetts, QurAlis employs proprietary platforms and biomarkers to create precision medicines that target genetically validated disease-causing alterations. The company’s pipeline includes innovative treatments aimed at specific subtypes of ALS, such as therapies that restore dysfunctional cellular waste clearance, manage overactive neurons, and eliminate toxic proteins. Through its advanced antisense oligonucleotides and small molecule programs, QurAlis seeks to halt disease progression and significantly improve patient outcomes for those affected by ALS.

Founded in Boston, Massachusetts in 2012, Riparian Pharmaceuticals is a biotechnology company dedicated to discovering novel therapeutics aimed at reversing endothelial dysfunction and enhancing human vascular health. The company focuses on innovative models of vascular pathophysiology to develop medical therapies targeting cardiovascular and inflammatory diseases.

Integrate multi-technology target screening and drug discovery to improve innovation development efficiency.

Dorian Therapeutics is a biotechnology company focused on developing innovative therapeutics aimed at treating age-associated diseases, including diabetes, Alzheimer's, arthritis, sarcopenia, osteoarthritis, and osteoporosis. The company specializes in rejuvenating cells and tissues by inhibiting the aging process in T cells, thereby enhancing their function, fitness, and longevity. Dorian Therapeutics also provides cellular and immunotherapy services that enable medical practitioners to reactivate regenerative processes, promoting youthfulness and improving health outcomes for patients affected by age-related conditions.

VersaPeutics, Inc. is a biotechnology company based in San Diego, California, founded in 2017. The company is dedicated to developing innovative treatments for disorders of the nervous system, specifically targeting conditions such as spinal cord injury, traumatic brain injury, and stroke. VersaPeutics aims to achieve breakthroughs in neurosciences to enhance diagnosis and treatment options for these complex medical challenges. The company is in the process of assembling a team of skilled scientists and business professionals to further its mission in the biopharmaceutical landscape.

VivaVision Biotech is a clinical-stage R&D biopharmaceutical company that is developing novel medicines to treat topical diseases. VivaVision Biotech is dedicated to bringing new therapeutics to millions of patients suffering from chronic ocular or dermal inflammatory diseases.

Arthrosi Therapeutics is a biotechnology company specializing in the discovery and development of innovative drugs aimed at treating gout and chronic kidney disease. The company is engaged in clinical-stage research, focusing on therapies that effectively reduce uric acid levels and address complications such as flare-ups and tophi in gout patients. By advancing its drug development efforts, Arthrosi Therapeutics seeks to enable healthcare providers to better manage the symptoms and long-term joint damage associated with gout, ultimately improving patient outcomes.

Dogma Therapeutics is a biotechnology company based in the United States focused on developing innovative treatments for lowering blood lipid levels. The company specializes in creating orally bioavailable small molecule inhibitors targeting proprotein convertase subtilisin/kexin type 9 (PCSK9). This approach aims to disrupt the interaction between PCSK9 and the LDL receptor, a challenging task due to the expansive binding interface. Dogma Therapeutics has achieved significant progress with picomolar affinity inhibitors, guided by high-resolution x-ray structures of their molecules bound to PCSK9.

Path Therapeutics, Inc. is a biotechnology company based in Calgary, Canada, focused on developing a novel neurometabolic, phenotypic drug discovery platform. This innovative platform aims to enhance drug discovery by identifying new protein targets and measuring improvements in mitochondrial function. By utilizing phenotypic screening technology, Path Therapeutics evaluates repurposed libraries with well-characterized molecular targets, facilitating the reverse identification of druggable proteins. The company's approach is particularly beneficial for addressing central nervous system disorders, including epilepsy, autism, and age-related conditions. Founded in 2013, Path Therapeutics seeks to enable de novo drug discovery and uncover novel mechanisms of action in the neuroscience field, with a focus on rare and pediatric epilepsies.

Flash is developing an oral compound to prevent AML relapse using novel findings linking HCK to AML. This small molecule will inhibit HCK and FLT3-ITD for the treatment of cancer. They have identified five potential compounds for further testing. One is moving on to IND filing while the other four are going to begin animal toxicology testing.

Epigenetic-based Cancer Diagnostics and Prognostics

Tabomedex Biosciences, Inc. is a biotechnology company based in Boxford, Massachusetts, founded in 2017. The company specializes in the research and development of innovative drug therapies for the treatment of type 2 diabetes. Its primary focus is on developing allosteric MK2 inhibitors, which enhance insulin sensitivity and exhibit significant cardioprotective effects. By targeting the MK2 pathway, Tabomedex aims to control blood glucose levels by inhibiting the activation of downstream enzymes associated with diabetes pathology. Through its scientific advancements, the company seeks to improve therapeutic outcomes for individuals affected by this condition.